The investment objective of the ARK Genomic Revolution Multi-Sector ETF seeks to invest in companies substantially focused on and are expected to substantially benefit from extending and enhancing the quality of human and other life by incorporating technological and scientific developments, improvements and advancements in genomics into their business. One such way this is accomplished is by offering new products or services that rely on genomic sequencing, analysis, synthesis or instrumentation. These companies may develop, produce or enable: Agricultural Biology, Bioinformatics, Bionic Medicine, DNA Sequencing, Instrumentation, Stem Cells, Pharmaceutical Innovation, Molecular Medicine and Diagnostics, and Bio-inspired Computing. The Fund is concentrated in any industry or group of industries in the health care sector, including, in particular, issuers having their principal business activities in the biotechnology industry. Other industries in the health-care sector include medical laboratories and research, drug manufacturers and agricultural chemicals.